Noxopharm looks at treating prostate cancer with Veyonda® in the LuPIN trial
02 Oct 2019 - Noxopharm Limited (ASX:NOX) Founder and Executive Chairman, Dr Graham Kelly, discusses early results on the use of Noxopharm's lead drug candidate, Veyonda, for the treatment of prostate cancer.